When is the next results date for Makers Labs.?

No Upcoming Board Meetings

What does Makers Labs. do?

Makers Laboratories Ltd manufactures pharmaceutical formulations and drug intermediates, classified as a Micro Cap company. As of March 2025, it reported net sales of 34 Cr and a market cap of Rs 95 Cr.

Overview:<BR>Makers Laboratories Ltd is engaged in the manufacture of pharmaceutical formulations and drug intermediates, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated in the State of Maharashtra in 1984 and commenced business on 21st July of that year. It underwent a status change with the amalgamation of Makers Drugs & Food Products Ltd. on 1st April 1993. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 34 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 95 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 12.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.06<BR>- Return on Equity: 11.76%<BR>- Price to Book: 1.36<BR><BR>Contact Details:<BR>Address: 54 D Kandivli Industrial Estate, Charkop Kandivli (West) Mumbai Maharashtra : 400067<BR>Tel: 91-22-2868 8544<BR>Email: investors@makerslabs.com<BR>Website: http://www.makerslabs.com

Has Makers Labs. declared dividend?

Makers Laboratories Ltd has declared a 10% dividend, amounting to 1 per share, but the dividend yield is 0%. While the company has shown significant price returns over various periods, dividends have not contributed to overall returns recently.

Makers Laboratories Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1<BR>- Ex-date: 01 Aug 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -1.64%, the dividend return was 0%, resulting in a total return of -1.64%.<BR><BR>For the 1-year period, the price return was 40.63%, the dividend return was 0%, leading to a total return of 40.63%.<BR><BR>Over the 2-year period, the price return was 54.5%, with a dividend return of 0%, culminating in a total return of 54.5%.<BR><BR>In the 3-year period, the price return was 10.17%, the dividend return was 0%, resulting in a total return of 10.17%.<BR><BR>During the 4-year period, the price return was -29.09%, with a dividend return of 0%, leading to a total return of -29.09%.<BR><BR>For the 5-year period, the price return was 292.08%, the dividend return was 0%, resulting in a total return of 292.08%.<BR><BR>Overall, while Makers Laboratories Ltd has declared a dividend, the dividend yield remains at 0%, indicating that dividends have not contributed to returns in recent periods. The total returns show significant variability, with particularly strong performance over the 5-year period.

Who are the peers of the Makers Labs.?

Peers of Makers Labs. include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Ind-Swift, Biofil Chemicals, Achyut Healthcar, Godavari Drugs, and Onyx Biotec. Makers Labs. has below-average management risk and growth compared to its peers, with a 1-year return of 30.42%.

Peers: The peers of Makers Labs. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ind-Swift, Biofil Chemicals, Achyut Healthcar, Godavari Drugs, and Onyx Biotec.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs., while Average management risk is found at Biofil Chemicals and Godavari Drugs. Below Average management risk is noted for Makers Labs., Achyut Healthcar, and Ind-Swift. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs., while Below Average growth is seen at Makers Labs., Divi's Lab., Torrent Pharma, Achyut Healthcar, and Ind-Swift. The Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs., while it is Good for Torrent Pharma, Average for Biofil Chemicals and Godavari Drugs, and Below Average for Makers Labs., Achyut Healthcar, and Ind-Swift.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Ind-Swift has the lowest at -19.94%. Makers Labs. has a 1-year return of 30.42%, which is significantly higher than Ind-Swift but lower than Divi's Lab. Additionally, the six-month returns are negative for Ind-Swift, Biofil Chemicals, Achyut Healthcar, and Godavari Drugs.

What is the technical trend for Makers Labs.?

As of June 5, 2025, Makers Labs shows a mildly bullish trend primarily supported by the weekly MACD and Bollinger Bands, despite some caution from daily moving averages and no clear signals from the RSI or Dow Theory.

As of 5 June 2025, the technical trend for Makers Labs has changed from sideways to mildly bullish. The weekly MACD is mildly bullish, supported by a bullish stance in both the weekly and monthly Bollinger Bands. The KST also indicates a mildly bullish trend on the weekly and bullish on the monthly. However, the daily moving averages are mildly bearish, which adds some caution to the overall outlook. The RSI shows no signal on both weekly and monthly time frames, and Dow Theory indicates no trend in either time frame. Overall, the current stance is mildly bullish, driven primarily by the MACD and Bollinger Bands.

Who are in the management team of Makers Labs.?

As of March 2023, the management team of Makers Labs includes R K P Verma (Chairman), Dipti Shah, Vishal Jain (Independent Directors), Prashant Godha (Non-Executive Director), Saahil U Parikh, Nilesh Jain (Executive Directors), and Surbhi Sharma (Company Secretary). They collectively oversee the company's governance and operations.

As of March 2023, the management team of Makers Labs includes the following individuals:<BR><BR>1. R K P Verma - Chairman & Independent Director<BR>2. Dipti Shah - Independent Non-Executive Director<BR>3. Vishal Jain - Independent Non-Executive Director<BR>4. Prashant Godha - Non-Executive & Non-Independent Director<BR>5. Saahil U Parikh - Non-Independent Executive Director<BR>6. Nilesh Jain - Non-Independent Executive Director<BR>7. Surbhi Sharma - Company Secretary & Compliance Officer<BR><BR>These members play various roles within the company, contributing to its governance and operational management.

Who are the top shareholders of the Makers Labs.?

The top shareholder of Makers Labs is Kaygee Investments Private Limited with a 17.38% stake, followed by public shareholder Tanvi Jignesh Mehta at 2.18%. Individual investors own 31.01% of the company, with no mutual funds or foreign institutional investors currently holding shares.

The top shareholders of Makers Labs include Kaygee Investments Private Limited, which holds the highest stake at 17.38%. The majority of the shares are held by promoters, and there are no pledged promoter holdings. In terms of public shareholders, Tanvi Jignesh Mehta is the largest, holding 2.18%. Additionally, individual investors collectively own 31.01% of the company. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in Makers Labs.

How big is Makers Labs.?

As of 24th July, Makers Laboratories Ltd has a market capitalization of 89.00 Cr, with recent net sales of 120.75 Cr and a net profit of 7.49 Cr. Shareholder's funds are 70.51 Cr, and total assets are valued at 147.95 Cr.

As of 24th July, Makers Laboratories Ltd has a market capitalization of 89.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 120.75 Cr and a Net Profit of 7.49 Cr.<BR><BR>For the latest annual period ending March 2025, the Shareholder's Funds amounted to 70.51 Cr, while Total Assets were valued at 147.95 Cr.

Should I buy, sell or hold Makers Labs.?

Are Makers Labs. latest results good or bad?

Makers Laboratories' latest results are concerning, showing a consolidated net loss of ₹0.12 crores in Q2 FY26, a decline from previous profits, despite a slight year-on-year sales growth. The company's declining profitability metrics and negative market reaction indicate that the results are viewed unfavorably by investors.

Makers Laboratories' latest results indicate a troubling performance for the company. In Q2 FY26, the consolidated net profit fell to a loss of ₹0.12 crores, marking a significant decline of 127.27% compared to the previous quarter. This stark loss contrasts sharply with the standalone net profit of ₹0.75 crores, which itself decreased by 41.86% from the prior quarter.<BR><BR>While net sales for the quarter were ₹34.17 crores, reflecting a slight sequential decline of 2.37%, they did show a year-on-year growth of 15.56%. However, this topline growth has not translated into improved profitability, as evidenced by the operating margin, which decreased to 6.67% from 8.60% in the previous quarter.<BR><BR>Overall, the company's financial performance is concerning, with significant losses at the consolidated level, declining profitability metrics, and operational challenges. The market has reacted negatively, as reflected in the stock's performance, which has been under pressure and trading near its 52-week low. This suggests that the latest results are viewed unfavorably by investors.

How has been the historical performance of Makers Labs.?

Makers Labs has shown fluctuating performance over the past five years, with net sales increasing to 120.75 Cr in March 2025, and a significant recovery in profitability, reporting a profit after tax of 10.91 Cr. However, the company faces challenges with negative cash flow of -4.00 Cr in March 2025.

Answer:<BR>The historical performance of Makers Labs shows a fluctuating trend in net sales and profitability over the past five years.<BR><BR>Breakdown:<BR>Makers Labs reported net sales of 120.75 Cr in March 2025, an increase from 104.39 Cr in March 2024 and 101.28 Cr in March 2023, but a decline from 126.63 Cr in March 2022. The total operating income mirrored this trend, reaching 120.75 Cr in March 2025. The company's total expenditure, excluding depreciation, was 112.36 Cr in March 2025, up from 103.34 Cr in March 2024, leading to an operating profit (PBDIT) of 8.39 Cr, a significant recovery from 1.05 Cr in the previous year. However, the operating profit margin (excluding other income) was 6.95% in March 2025, compared to 1.01% in March 2024. Profit before tax improved to 13.41 Cr in March 2025, recovering from a loss of 3.92 Cr in March 2024, while profit after tax was 10.91 Cr, a turnaround from a loss of 4.81 Cr the previous year. The consolidated net profit for March 2025 was 7.49 Cr, compared to a loss of 6.26 Cr in March 2024. The company's total assets decreased to 147.95 Cr in March 2025 from 161.26 Cr in March 2024, and total liabilities also fell to 147.95 Cr from 161.26 Cr. Cash flow from operating activities was negative at -4.00 Cr in March 2025, contrasting with a positive cash flow of 0.00 Cr in March 2024. Overall, while Makers Labs has shown signs of recovery in sales and profitability, it continues to face challenges in cash flow management.

Is Makers Labs. overvalued or undervalued?

As of November 10, 2025, Makers Labs. is considered overvalued with a PE ratio of -4693.22, unfavorable comparisons to peers like Sun Pharma and Cipla, and a significant year-to-date stock decline of 34% versus the Sensex's gain of 6.91%.

As of 10 November 2025, the valuation grade for Makers Labs. has moved from very attractive to very expensive. This indicates a significant shift in the company's perceived value, suggesting that it is currently overvalued. The company's PE ratio stands at an alarming -4693.22, while its EV to EBITDA is 8.94 and EV to Sales is 0.66, which are concerning figures in the context of its financial health.<BR><BR>In comparison to its peers, Makers Labs. is positioned unfavorably against companies like Sun Pharma. Inds., which has a PE ratio of 35.15 and an EV to EBITDA of 10.64, and Cipla, which boasts a PE ratio of 22.45 and an EV to EBITDA of 5.67. The stark contrast in these ratios highlights the overvaluation of Makers Labs. Furthermore, the company's stock has underperformed the Sensex significantly over various periods, with a year-to-date decline of 34.00% compared to the Sensex's gain of 6.91%. Overall, the evidence strongly supports that Makers Labs. is overvalued in the current market.

Which are the latest news on Makers Labs.?

Why is Makers Labs. falling/rising?

As of 04-Dec, Makers Laboratories Ltd's stock price is rising to 123.00, reflecting a short-term recovery despite a year-to-date decline of 32.06%. The recent gains indicate positive momentum, but decreased investor participation suggests potential challenges ahead.

As of 04-Dec, Makers Laboratories Ltd's stock price is rising, currently at 123.00, reflecting an increase of 4.75 (4.02%). The stock has outperformed the sector by 3.73% today and has been on a consecutive gain for the last two days, accumulating a total return of 7.1% during this period. The stock opened with a gain of 2.33% today and reached an intraday high of Rs 124, indicating strong positive momentum.<BR><BR>Despite the overall negative performance over longer periods, such as a year-to-date decline of 32.06% and a 1-year drop of 26.70%, the recent performance suggests a short-term recovery. However, it is important to note that there has been a decrease in investor participation, with delivery volume falling by 57.58% against the 5-day average, which could indicate a lack of sustained interest. Overall, the current rise in stock price is primarily driven by recent gains and positive short-term performance metrics.